Julie Decock
Khalifa University
Matrix metalloproteinaseCancerInternal medicinePathologyOncologyTranscriptomeExtracellular matrixImmunologyImmunotherapyMetastasisTriple-negative breast cancerAngiogenesisLymph nodeImmune checkpointCancer/testis antigensCancer researchBreast cancerCarcinogenesisMedicineBiologyImmune systemCancer cell
56Publications
20H-index
1,149Citations
Publications 57
Newest
#1Adviti Naik (Khalifa University)H-Index: 8
#2Remy Thomas (Khalifa University)H-Index: 6
Last. Julie Decock (Khalifa University)H-Index: 20
view all 6 authors...
PReferentially expressed Antigen in Melanoma (PRAME) is a cancer testis antigen with restricted expression in somatic tissues and re-expression in poor prognostic solid tumours. PRAME has been extensively investigated as a target for immunotherapy, however, its role in modulating the anti-tumour immune response remains largely unknown. Here, we show that PRAME tumour expression is associated with worse survival in the TCGA breast cancer cohort, particularly in immune-unfavourable tumours. Using ...
Source
Background null Cancer testis antigens (CTAs) are lucrative anti-cancer targets given their restricted expression patterns and known roles as mediators of cancer hallmarks, including cancer metabolism, proliferation, survival, and cell motility. Lactate dehydrogenase C (LDHC) is a CTA with upregulated expression in poor prognosis subtypes of breast cancer, however its tumorigenic role is less understood. We recently reported that silencing LDHC reduces breast cancer cell survival through a dysre...
Source
Source
#1Adviti Naik (Khalifa University)H-Index: 8
#2Julie Decock (Khalifa University)H-Index: 20
The cancer testis antigen (CTA) lactate dehydrogenase C (LDHC) is a promising anti-cancer target with tumor-specific expression and immunogenicity. Interrogation of breast cancer patient cohorts from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) indicate that upregulation of LDHC expression correlates with unfavorable prognosis. Although the role of LDHC is well characterized in spermatocytes, its role in tumors remains largely unknown...
Source
The cancer testis antigen (CTA) lactate dehydrogenase C (LDHC) is a promising anti-cancer target with tumor-specific expression, immunogenicity and a role in metabolic reprogramming. Interrogation of the TCGA breast cancer cohort demonstrates upregulation of LDHC expression, conferring unfavorable prognosis. Although the role of LDHC is well characterized in spermatocytes, its role in tumors remains largely unknown. We investigated whether LDHC is involved in regulating genomic stability and may...
Source
#1Remy Thomas (Khalifa University)H-Index: 6
#2Ghaneya Al-Khadairi (Khalifa University)H-Index: 4
Last. Julie Decock (Khalifa University)H-Index: 20
view all 3 authors...
Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to kill tumors and revolutionizing cancer treatment in a variety of cancers. Although breast cancer was historically believed to be immunologically silent, treatment with immune checkpoint inhibitors has been shown to induce modest responses in metast...
Source
#1Jessica Roelands (Qatar Airways)H-Index: 9
#2Raghvendra Mall (Qatar Computing Research Institute)H-Index: 16
Last. Rosalyn W. Sayaman (Beckman Research Institute)H-Index: 7
view all 14 authors...
Breast cancer largely dominates the global cancer burden statistics; however, there are striking disparities in mortality rates across countries. While socioeconomic factors contribute to population-based differences in mortality, they do not fully explain disparity among women of African ancestry (AA) and Arab ancestry (ArA) compared to women of European ancestry (EA). In this study, we sought to identify molecular differences that could provide insight into the biology of ancestry-associated d...
Source
#1Adviti Naik (Khalifa University)H-Index: 8
#2Julie Decock (Khalifa University)H-Index: 20
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with poor prognosis, early recurrence, and the lack of durable chemotherapy responses and specific targeted treatments. The recent FDA approval for immune checkpoint inhibition in combination with nab-paclitaxel for the treatment of metastatic TNBC created opportunity to advocate for immunotherapy in TNBC patients. However, improving the current low response rates is vital. Most cancers, including TNBC tumo...
Source
Background Cancer testis antigens (CTAs) have gained interest in the field of anti-cancer therapy as they offer the opportunity to target tumor cells with little off/on-target side effects given their restricted expression patterns. Several CTAs have been implicated as mediators of cancer hallmarks including cancer metabolism, proliferation, survival, and cell motility. Lactate dehydrogenase C (LDHC) expression has been observed in various cancer types and likely confers a survival advantage to ...
Source
#1Salman M Toor (Khalifa University)H-Index: 16
#2Varun Sasidharan Nair (Khalifa University)H-Index: 17
Last. Eyad Elkord (University of Manchester)H-Index: 35
view all 4 authors...
Abstract Interactions between immune checkpoints (ICs) and their ligands negatively regulate T cell activation pathways involved in physiological immune responses against specific antigens. ICs and their ligands are frequently upregulated in the tumor microenvironment (TME) of various malignancies, and they represent significant barriers for induction of effective anti-tumor immune responses. Several IC inhibitors (ICIs) have been developed, with some currently in clinical trials and others bein...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.